Corcept Therapeutics Incorporated (CORT)
Automate Your Wheel Strategy on CORT
With Tiblio's Option Bot, you can configure your own wheel strategy including CORT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CORT
- Rev/Share 7.158
- Book/Share 6.1027
- PB 6.6692
- Debt/Equity 0.0101
- CurrentRatio 3.1413
- ROIC 0.1005
- MktCap 4281160432.0
- FreeCF/Share 1.57
- PFCF 26.3349
- PE 40.0654
- Debt/Assets 0.0077
- DivYield 0
- ROE 0.1599
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CORT | Wolfe Research | Peer Perform | Underperform | -- | $30 | Dec. 31, 2025 |
| Initiation | CORT | UBS | -- | Neutral | -- | -- | Dec. 16, 2025 |
| Initiation | CORT | Wolfe Research | -- | Peer Perform | -- | -- | Nov. 18, 2025 |
News
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CORCEPT THERAPEUTICS INCORPORATED (CORT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On December 31, 2025, Corcept announc.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept Therapeutics Incorporated – CORT
Published: February 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
Published: February 02, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant – came on January 30, 2026 when Reuters reported that the FDA "warned the company 'on several occasions' not to submit its drug application." This news sent the price of Corcept shares tumbling $7.81 (-17%) during trading that day.
Read More
Corcept Therapeutics (CORT) Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application – Hagens Berman
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant – came on January 30, 2026 when Reuters reported that the FDA “warned the company ‘on several occasions' not to submit its drug application.” This news sent the price of Corcept shares tumbling $7.81 (-17%) during trading that day.
Read More
Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, announces that it is investigating potential securities law violations by Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept” or the “Company”), a company based in Redwood City, California.
Read More
Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Securities Class Action Investigation – CORT
Published: January 30, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT) resulting from allegations that Corcept may have issued materially misleading business information to the investing public. So What: If you purchased Corcept securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe.
Read More
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Corcept Theraepeutics Incorporated (NASDAQ: CORT)? Did you lose money in your investment in Corcept Theraepeutics Incorporated?
Read More
Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Corcept Therapeutics Inc. (Nasdaq: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about how they might recover those losses.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: January 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Neutral
Corcept jumps after relacorilant plus nab-paclitaxel hits overall survival endpoint in phase III ROSELLA study in platinum-resistant ovarian cancer.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: January 22, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: January 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman
Published: January 14, 2026 by: PRNewsWire
Sentiment: Neutral
Partner Reed Kathrein Urges Investors to Contact Firm SAN FRANCISCO, Jan. 14, 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL") from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant. The news and severe market reaction has prompted national shareholder rights law firm Hagens Berman to commence an investigation into whether Corcept may have misled investors about relacorilant's efficacy and commercial prospects.
Read More
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Corcept Therapeutics Incorporated (CORT)
Published: January 14, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws. What Happened?
Read More
CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses
Published: January 13, 2026 by: Newsfile Corp
Sentiment: Neutral
Boston, Massachusetts--(Newsfile Corp. - January 13, 2026) - Block & Leviton is investigating Corcept Therapeutics Inc. (NASDAQ: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about how they might recover those losses.
Read More
Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT)
Published: January 12, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 12, 2026) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.
Read More
CORT Investor ALERT: Corcept Therapeutics Inc. Investigated for Securities Fraud; Investors Should Contact Block & Leviton To Potentially Recover Losses
Published: January 12, 2026 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Corcept Therapeutics Inc. (Nasdaq: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about how they might recover those losses.
Read More
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter (“CRL”) from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: January 08, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT)
Published: January 07, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 7, 2026) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.
Read More
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman
Published: January 06, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, Jan. 6, 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL") from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant. The news and severe market reaction has prompted national shareholder rights law firm Hagens Berman to commence an investigation into whether Corcept may have misled investors about relacorilant's efficacy and commercial prospects.
Read More
Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains?
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Negative
CORT's shares plunge after the FDA issues a CRL to relacorilant's new drug application for treating patients with hypercortisolism.
Read More
Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?
Published: December 22, 2025 by: Benzinga
Sentiment: Negative
Are There Red Flags in the Trial Results?
Read More
Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Read More
Will Korlym Continue to Drive Corcept's Top Line in 2026?
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
CORT leans on rising Korlym sales while awaiting key relacorilant FDA decisions that could broaden its growth path in 2026.
Read More
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues.
Read More
Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.
Read More
Corcept Transition To New Specialty Pharmacy Well Underway
Published: October 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Corcept Therapeutics (CORT) has added Curant Rare as a second specialty pharmacy to handle increased prescription demand for Korlym. Optime Care will discontinue servicing CORT prescriptions due to its preference for exclusive partnerships, causing some market confusion. CORT management and sell-side analysts confirm Curant Health is smoothly processing all new prescription growth, ensuring continuity.
Read More
About Corcept Therapeutics Incorporated (CORT)
- IPO Date 2004-04-14
- Website https://www.corcept.com
- Industry Biotechnology
- CEO Joseph K. Belanoff
- Employees 500